Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Autor: Alexandra Calmy, Tamara Tovar Sanchez, Charles Kouanfack, Mireille Mpoudi-Etame, Sandrine Leroy, Ségolène Perrineau, Martial Lantche Wandji, Darius Tetsa Tata, Pierette Omgba Bassega, Thérèse Abong Bwenda, Marie Varloteaux, Marcel Tongo, Eitel Mpoudi-Ngolé, Alice Montoyo, Noémie Mercier, Vincent LeMoing, Martine Peeters, Jacques Reynes, Eric Delaporte, A Calmy, T Tovar Sanchez, C Kouanfack, M Mpoudi-Etame, S Leroy, S Perrineau, M Lantche-Wandji, D Tetsa-Tata, P Omgba-Bassega, T Abong-Bwenda, M Varloteaux, M Tongo, E Mpoudi-Ngolé, A Montoyo, N Mercier, V LeMoing, M Peeters, J Reynes, E Delaporte, A Ayouba, A Agholeng, C Butel, A Cournil, S Eymard-Duvernay, B Granouillac, S Izard, A Lacroix, L Serrano, N Vidal, PJ Fouda, R Mougnoutou, J Olinga, V Omgba, SC Tchokonte-Ngandé, B Ymele, CD Epoupa-Mpacko, M Fotso, R Moukoko, T Nké, A Akamba, S Lekelem, SB Tongo-Fotack, S Ngono, M Tanga, E Ebong, G Edoul-Mbesse, L Ciaffi, S Koulla-Shiro, G Manirakiza, ED Mimbé, S Boyer, M Bousmah, G Maradan, ML Nishimwe, B Spire, MP Lê, G Peytavin, A Diallo, I Fournier, C Rekacewicz, C Perez Casas

Publikováno v: The Lancet HIV
The Lancet HIV, 2020, 7 (10), pp.e677-e687. ⟨10.1016/S2352-3018(20)30238-1⟩

International audience; Background: Updated WHO guidelines recommend a dolutegravir-based regimen as the preferred first-line treatment for HIV infection and low-dose efavirenz (400 mg) as an alternative. We aimed to report the non-inferior efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e04f3e8044bec57d70cb397c548401b0
https://hal.umontpellier.fr/hal-03337700

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.